Protara Therapeutics, Inc. (TARA)
- Previous Close
3.0500 - Open
3.0400 - Bid 2.9700 x 100
- Ask 3.1200 x 100
- Day's Range
2.8200 - 3.1813 - 52 Week Range
1.0400 - 5.2400 - Volume
395,404 - Avg. Volume
248,161 - Market Cap (intraday)
34.53M - Beta (5Y Monthly) 1.88
- PE Ratio (TTM)
-- - EPS (TTM)
-3.5700 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.80
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
www.protaratx.comRecent News: TARA
Performance Overview: TARA
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TARA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TARA
Valuation Measures
Market Cap
34.99M
Enterprise Value
-25.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.58
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.36%
Return on Equity (ttm)
-47.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-40.42M
Diluted EPS (ttm)
-3.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
65.58M
Total Debt/Equity (mrq)
8.00%
Levered Free Cash Flow (ttm)
-21.88M